Introduction
The best treatment strategy for in-stent chronic total occlusion (CTO) after drug-eluting stent (DES) implantation has not yet been established. One option would be implantation of the newer generation DES into DES-CTO. We here report a case with instent CTO of the first generation DES, sirolimus-eluting stent (SES) (Cypher ® , Cordis, Miami Lakes, FL, USA). He was successfully treated with implantation of another DES, an Endeavor-zotarolimus-eluting stent (E-ZES, Medtronic, Santa Rosa, CA, USA) into SES-CTO. E-ZES is characterized by more rapid release of the bio-suppressive drug and the greater late loss than other DES. Coronary angioscopy (CAS) and optical coherence tomography (OCT) revealed the favorable plaque sealing process during the follow-up period of 50 months.
Case Description
In 2004, a 69-year-old man with unstable angina underwent percutaneous coronary intervention (PCI). The target lesion was severe stenosis of the first diagonal branch of his left coronary artery. His coronary risk factors were hypertension, dyslipidemia, and cigarette smoking. The lesion was successfully treated with the first generation DES, SES of 2.5x18mm.
In 2010, prior to his major surgery, he was subjected to coronary angiography (CAG). It showed CTO at the stented site, indicating at 33 months were similar to those at 50 months. CAS showed the luminal appearance of E-ZES (Figure 3) . At 8 months, stent struts were covered with the thin transparent neointima ( Figure 3A,3B) . At 15 months, stent struts were covered with white thicker neointimal but still bulged into the lumen without glossy appearance ( Figure  3C,3D) . At 50 months, stent struts were fully embedded with white neointimal and not visible ( Figure 3E,3F) . OCT (Dragonfly TM Imaging Catheter, St, Jude Medical, St. Paul, MN, USA) showed the relatively thinner neointimal stent coverage at 15 months ( Figure 3C' ,3D' ) and the thicker homogeneous coverage at 50 months ( Figure 3E' ,3F' ), confirming the favorable plaque sealing after E-ZES implantation.
Discussion
Up to 50 months after E-ZES implantation into SES-CTO, CAG showed patency of the treated vessel (Figure 2 ). CAS and OCT showed the favorable plaque sealing with white neointima (Figure 3 ). Previously-proposed strategies for DES-CTO were cutting balloon angioplasty [1] , additional implantation of SES or everolimus-eluting stents [2] , and paclitaxel-coated balloon [3] . We would propose that additional E-ZES implantation into SES-CTO was another option for SES-CTO treatment.
We previously reported with CAS that SES-CTO was characterized by massive thrombi and yellow plaque ( Figure 1B,C) , indicating that neoatherosclerosis progressed after SES implantation [4] . We also reported the relatively rapid healing process of E-ZESrelated coronary perforation [5] and pseudoaneurysm [6] . Although a comparative study with many patients is necessary to verify our proposal, this case report suggested that E-ZES implantation into SES-CTO might lead to favorable plaque sealing with white neointimal (Figure 3) . Characteristics of E-ZES are rapid release of zotarolimus and the greater late loss at chronic phase, allowing us to speculate that vascular healing process after E-ZES implantation would be similar to that after implantation of bare metal stents (BMS). Previous study with CAS reported the plaque sealing phenomenon after BMS implantation in patients with acute myocardial infarction [7] . It still remains unclear whether BMS implantation into SES-CTO would result in a similar outcome to E-ZES implantation.
In-stent neoatherosclerosis has been well characterized in vivo with CAS and OCT. The former visualizes endothelial coverage on stent struts, in-stent mural thrombi, and yellow plaque [8] . The latter quantifies in-stent plaque burden. To diagnose plague vulnerability, CAS is superior to OCT.
In conclusion, we report a case with the favorable plaque sealing of SES-CTO after additional E-ZES implantation. F) . In-stent OCT images were recorded at 15 months (C',D') and 50 months after the E-ZES deployment (E',F'). Sites of angioscopic and OCT images were indicated by arrows in figure 2 .
